|
1
|
Burisch J, Claytor J, Hernandez I, Hou JK
and Kaplan GG: The cost of inflammatory bowel disease care: How to
make it sustainable. Clin Gastroenterol Hepatol. 23:386–395.
2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Aswani-Omprakash T, Sharma V, Bishu S,
Balasubramaniam M, Bhatia S, Nandi N, Shah ND, Deepak P and
Sebastian S: Addressing unmet needs from a new frontier of IBD: The
South Asian IBD Alliance. Lancet Gastroenterol Hepatol. 6:884–885.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Balasubramaniam M, Nandi N,
Aswani-Omprakash T, Sebastian S, Sharma V and Deepak P: South Asian
Ibd Alliance Board Of Directors. Identifying care challenges as
opportunities for research and education in inflammatory bowel
disease in South Asia. Gastroenterology. 163:1145–1150.
2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rana VS, Mahajan G, Patil AN, Singh AK,
Jearth V, Sekar A, Singh H, Saroch A, Dutta U and Sharma V: Factors
contributing to flares of ulcerative colitis in North India-a
case-control study. BMC Gastroenterol. 23(336)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Noor NM, Lee JC, Bond S, Dowling F,
Brezina B, Patel KV, Ahmad T, Banim PJ, Berrill JW, Cooney R, et
al: A biomarker-stratified comparison of top-down versus
accelerated step-up treatment strategies for patients with newly
diagnosed Crohn's disease (PROFILE): A multicentre, open-label
randomised controlled trial. Lancet Gastroenterol Hepatol.
9:415–427. 2024.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bayoumy AB, Mulder CJJ, Ansari AR, Barclay
ML, Florin T, Kiszka-Kanowitz M, Derijks L, Sharma V and de Boer
NKH: Uphill battle: Innovation of thiopurine therapy in global
inflammatory bowel disease care. Indian J Gastroenterol. 43:36–47.
2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pal P, Banerjee R, Vijayalaxmi P, Reddy DN
and Tandan M: Depression and active disease are the major risk
factors for fatigue and sleep disturbance in inflammatory bowel
disease with consequent poor quality of life: Analysis of the
interplay between psychosocial factors from the developing world.
Indian J Gastroenterol. 43:226–236. 2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sharma V, Shukla J, Suri V, Jena A,
Mukerjee A, Mandavdhare HS, Bhalla A and Dutta U: Cost concerns,
not the guidelines, drive clinical care of IBD during COVID
pandemic in a resource limited setting. Expert Rev Gastroenterol
Hepatol. 15:465–466. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Travis SP, Farrant JM, Ricketts C, Nolan
DJ, Mortensen NM, Kettlewell MG and Jewell DP: Predicting outcome
in severe ulcerative colitis. Gut. 38:905–910. 1996.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ain SN, Khan ZA and Gilani MA: Revised
kuppuswamy scale for 2021 based on new consumer price index and use
of conversion factors. Indian J Public Health. 65:418–421.
2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kamat N, Ganesh Pai C, Surulivel Rajan M
and Kamath A: Cost of illness in inflammatory bowel disease. Dig
Dis Sci. 62:2318–2326. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pakdin M, Zarei L, Bagheri Lankarani K and
Ghahramani S: The cost of illness analysis of inflammatory bowel
disease. BMC Gastroenterol. 23(21)2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Odes S, Vardi H, Friger M, Wolters F,
Russel MG, Riis L, Munkholm P, Politi P, Tsianos E, Clofent J, et
al: Cost analysis and cost determinants in a european inflammatory
bowel disease inception cohort with 10 years of follow-up
evaluation. Gastroenterology. 131:719–728. 2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kappelman MD, Rifas-Shiman SL, Porter CQ,
Ollendorf DA, Sandler RS, Galanko JA and Finkelstein JA: Direct
health care costs of crohn's disease and ulcerative colitis in US
children and adults. Gastroenterology. 135:1907–1913.
2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bassi A, Dodd S, Williamson P and Bodger
K: Cost of illness of inflammatory bowel disease in the UK: A
single centre retrospective study. Gut. 53:1471–1478.
2004.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Van Linschoten RCA, Visser E, Niehot CD,
Van Der Woude CJ, Hazelzet JA, Van Noord D and West RL: Systematic
review: Societal cost of illness of inflammatory bowel disease is
increasing due to biologics and varies between continents. Aliment
Pharmacol Ther. 54:234–248. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM
and Chao J: Systematic review: The costs of ulcerative colitis in
Western countries. Aliment Pharmacol Ther. 31:693–707.
2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Khalili H, Everhov ÅH, Halfvarson J,
Ludvigsson JF, Askling J, Myrelid P, Söderling J, Olen O and
Neovius M: SWIBREG Group. Healthcare use, work loss and total costs
in incident and prevalent Crohn's disease and ulcerative colitis:
Results from a nationwide study in Sweden. Aliment Pharmacol Ther.
52:655–668. 2020.PubMed/NCBI View Article : Google Scholar
|
